Tobam trimmed its holdings in Incyte Co. (NASDAQ:INCY) by 6.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 154,892 shares of the biopharmaceutical company’s stock after selling 10,306 shares during the period. Tobam owned approximately 0.07% of Incyte worth $10,700,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of INCY. Rhumbline Advisers boosted its holdings in Incyte by 1.1% in the third quarter. Rhumbline Advisers now owns 367,549 shares of the biopharmaceutical company’s stock valued at $25,390,000 after purchasing an additional 4,076 shares during the period. Candriam Luxembourg S.C.A. boosted its holdings in Incyte by 6.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 315,795 shares of the biopharmaceutical company’s stock valued at $21,815,000 after purchasing an additional 18,935 shares during the period. Nomura Asset Management Co. Ltd. boosted its holdings in Incyte by 4.6% in the third quarter. Nomura Asset Management Co. Ltd. now owns 39,575 shares of the biopharmaceutical company’s stock valued at $2,734,000 after purchasing an additional 1,723 shares during the period. Toronto Dominion Bank boosted its holdings in Incyte by 1.8% in the third quarter. Toronto Dominion Bank now owns 115,547 shares of the biopharmaceutical company’s stock valued at $7,980,000 after purchasing an additional 2,051 shares during the period. Finally, ARK Investment Management LLC boosted its holdings in Incyte by 44.9% in the third quarter. ARK Investment Management LLC now owns 63,643 shares of the biopharmaceutical company’s stock valued at $4,396,000 after purchasing an additional 19,719 shares during the period. Institutional investors own 92.21% of the company’s stock.

INCY opened at $64.15 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.01 and a current ratio of 4.02. Incyte Co. has a one year low of $58.33 and a one year high of $108.25. The stock has a market cap of $13.38 billion, a PE ratio of 100.23 and a beta of 1.12.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.38 EPS for the quarter, missing the Zacks’ consensus estimate of $0.40 by ($0.02). Incyte had a positive return on equity of 2.23% and a negative net margin of 6.07%. The firm had revenue of $449.68 million for the quarter, compared to analyst estimates of $448.34 million. During the same quarter last year, the firm posted $0.19 EPS. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. As a group, equities research analysts anticipate that Incyte Co. will post 0.43 EPS for the current year.

In other news, Director Jean Jacques Bienaime bought 1,000 shares of the business’s stock in a transaction dated Thursday, November 8th. The shares were acquired at an average price of $68.77 per share, for a total transaction of $68,770.00. Following the completion of the transaction, the director now owns 6,168 shares of the company’s stock, valued at $424,173.36. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Paul Trower sold 10,000 shares of Incyte stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $70.00, for a total value of $700,000.00. Following the sale, the insider now owns 24,172 shares in the company, valued at approximately $1,692,040. The disclosure for this sale can be found here. Insiders have sold 31,000 shares of company stock worth $2,202,100 in the last quarter. Insiders own 17.20% of the company’s stock.

A number of research firms recently issued reports on INCY. Argus set a $83.00 target price on Incyte and gave the company a “buy” rating in a report on Thursday, August 30th. BidaskClub upgraded Incyte from a “buy” rating to a “strong-buy” rating in a report on Friday, August 31st. Cowen reiterated a “buy” rating on shares of Incyte in a report on Tuesday, September 4th. Raymond James restated a “buy” rating on shares of Incyte in a research note on Friday, July 27th. Finally, Zacks Investment Research upgraded Incyte from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a research note on Friday, July 20th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Incyte presently has an average rating of “Hold” and an average price target of $94.48.

COPYRIGHT VIOLATION WARNING: “Tobam Sells 10,306 Shares of Incyte Co. (INCY)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/11/15/tobam-sells-10306-shares-of-incyte-co-incy.html.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Article: Exchange-Traded Funds (ETFs)

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.